Discovery Life Sciences and Mindpeak have established a strategic partnership to advance AI-powered digital pathology, aiming to transform biomarker analysis in global clinical trials and drive innovation in cancer diagnostics.
Aiming to improve drug development and patient stratification, the partnership targets resolving inconsistent biomarker interpretation among pathologists by enhancing accuracy and consistency in interpreting immunohistochemistry (IHC) and multiplex immunofluorescence (mIF).
"This collaboration with Discovery Life Sciences provides access to our AI platform, training and microdissection tools, supporting researchers in IHC and mIF applications and helping to drive greater consistency and confidence in biomarker assessment," said Felix Faber, founder and CEO of Mindpeak.
AI-powered digital pathology
Mindpeak's AI platform and Discovery's biomarker laboratory services aim to standardise interpretation and enhance reproducibility in regulated clinical settings.
Mindpeak's technology will support AI-enabled image analysis, workflow optimisation, and microdissection tools that precisely isolate specific tissue regions. It also includes training to enhance interpretation. These capabilities are designed to act as a safeguard in biomarker-driven trials, reducing variability and strengthening confidence in go/no-go decisions.
"As AI use in pathology increases for clinical research, this partnership with Mindpeak allows integration of modelling tools that can enable improved accuracy in biomarker analysis," said Greg Herrema, CEO of Discovery Life Sciences. "Combining these AI capabilities with our clinical trials expertise will help advance the development of biomarker-focused therapies."
The companies plan to present further details of the collaboration at the AACR Annual Meeting 2026 in San Diego, where they will showcase innovative use cases and applications for clinical research.
